Previous business/academic article Next business/academic article
Business Articles Awards > Intellectual Property

What FTC Is Saying in 1st Post-Actavis Pay-For-Delay Case

Paul M. Eckles, Karen H. Lent, Sharis A. Pozen and Steven C. Sunshine, Law 360, September 2014

See Paul M. Eckles's resume See Steven C. Sunshine's resume See Sharis Pozen's resume See Karen Hoffman Lent's resume

Click here to read the full article online

On Sept. 8, 2014, the Federal Trade Commission filed a federal antitrust complaint in the United States District Court for the Eastern District of Pennsylvania against defendants AbbVie Inc., Abbott Laboratories Inc., Unimed Pharmaceuticals LLC, Besins Healthcare Inc. and Teva Pharmaceuticals Industries Inc. alleging violations of Section 5 of the FTC Act, 15 U.S.C. § 45(a), for entering into an agreement to maintain a monopoly over and restrain generic competition to AndroGel, a testosterone replacement therapy product.

© 2017 - Institute of Competition Law Download our brochure